Motility Disorders Irritable Bowel Syndrome
responsible for the phenotype of the PR in an individual, has to remain open at this stage, but will be subject to future research.
The PR in functional gastrointestinal diseases is a significant confounder of the assessment of drug efficacy in clinical trials. However, as in many conditions in medicine, it is an effective component in the reduction of human suffering, and insights into its mechanisms enhance ‘active’ treatments and open up new vistas for maximizing medical success. The psychobiologic basis of the PR is the subject of ongoing clinical research. n
1. 2. 3. 4.
Enck P, Benedetti F, Schedlowski M, New insights into the placebo and nocebo responses, Neuron, 2008;59:195–206.
Mearin F, Balboa A, Zarate N, et al., Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses, Am J Gastroenterol, 1999;94:116–25.
Allescher HD, Bockenhoff A, Knapp G, et al., Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies, Scand J Gastroenterol, 2001;36:934–41.
Ford AC, Talley NJ, Spiegel BM, et al., Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta- analysis, BMJ, 2008;337:a2313.
Ford AC, Talley NJ, Schoenfeld PS, et al., Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis, Gut, 2009;58:367–78.
Ford AC, Brandt LJ, Young C, et al., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis, Am J Gastroenterol, 2009;104(7):1831–43.
7. Lesbros-Pantoflickova D, Michetti P, et al., Meta-analysis: The treatment of irritable bowel syndrome, Aliment Pharmacol Ther, 2004;20:1253–69.
Hoveyda N, Heneghan C, Mahtani KR, et al., A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome, BMC Gastroenterol, 2009;9:15.
Dorn SD, Kaptchuk TJ, Park JB, et al., A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome, Neurogastroenterol Motil, 2007;19:630–7.
10. 11. 12. 13. 14.
Spiller RC, Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials, Am J Med, 1999;107(Suppl.):91–7.
Pitz M, Cheang M, Bernstein CN, Defining the predictors of the placebo response in irritable bowel syndrome, Clin Gastroenterol Hepatol, 2005;3:237–47.
Patel SM, Stason WB, Legedza A, et al., The placebo effect in irritable bowel syndrome trials: a meta-analysis, Neurogastroenterol Motil, 2005;17:332–40.
Enck P, Klosterhalfen S, The placebo response in functional bowel disorders: perspectives and putative mechanisms, Neurogastroenterol Motil, 2005;17:325–31.
Kirsch I, Sapirstein G, Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention and Treatment, 1998. Available at: journals.apa.org/pt/prevention/volume1/pre0010002a
. html (accessed December 2, 2009).
15. 16. 17.
Ilnyckyj A, Shanahan F, Anton PA, et al., Quantification of the placebo response in ulcerative colitis, Gastroenterology, 1997;112:1854–8.
Garud S, Brown A, Cheifetz A, et al., Meta-analysis of the placebo response in ulcerative colitis, Dig Dis Sci, 2008;53(4):875–91.
Su C, Lichtenstein GR, Krok K, et al., A meta-analysis of the placebo response rates of remission and response in clinical trials of active Crohn’s disease, Gastroenterology, 2004;126:1257–69.
18. 32 Bridge JA, Birmaher B, Iyengar S, et al., Placebo response 28. 29. 30. 31. 32. 33. 34. 35. 19.
Paul Enck, PhD, is Director of Research in the Department of Psychosomatic Medicine and Psychotherapy at University Hospital Tübingen. His main interests are the psychophysiology and neurobiology of the placebo response, of eating and food intake and its disorders, of nausea and vomiting, and of gut functions in health and disease, including functional and inflammatory bowel disorders. He has published more than 130 original papers in peer-reviewed journals and
more than 200 book chapters and review articles. He is a Board Member/Treasurer of the European Society of Neurogastroenterology and Motility.
in randomized controlled trials of antidepressants for pediatric major depressive disorder, Am J Psychiatry, 2008;166:42–9.
Kirsch I, Deacon BJ, Huedo-Medina TB, et al., Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration, PLoS Med, 2008;5(2):e45.
Enck P, Vinson B, Malfertheiner P, et al., Placebo effects in functional dyspepsia—reanalysis of trial data, Neurogastroenterol Motil, 2009;21:370–7.
van Die MD, Bone KM, Burger HG, Teede HJ, Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial, BMC Med Res Methodol, 2009;9:41.
22. 23. 24. 25. 26.
Moerman DE, Jonas WB, Deconstructing the placebo effect and finding the meaning response, Ann Intern Med, 2002;136:471–6.
de Craen AJ, Moerman DE, Heisterkamp SH, et al., Placebo effect in the treatment of duodenal ulcer, Br J Clin Pharmacol, 1999;48:853–60.
Moerman DE, Cultural variations in the placebo effect: ulcers, anxiety, and blood pressure, Med Anthropol Q, 2000;14:51–72.
Hrobjartsson A, Gotzsche PC, Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment, N Engl J Med, 2001;344:1594–1602.
Hrobjartsson A, Gotzsche PC, Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment, J Intern Med, 2004;256:91–100.
Krogsbøll LT, Hrobjartsson A, Gøtzsche PC, Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention, BMC Med Res Methodol, 2009;9:1.
Vase L, Riley JL 3rd, Price DD, A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia, Pain, 2002;99:443–52.
Kirsch I, Are drug and placebo effects in depression additive?, Biol Psychiatry, 2000;47:733–5.
Enck P, Klosterhalfen S, Weimer K, et al., The placebo response in clinical trials—more questions than answers, Phil Trans Roy Soc B, 2010; in press.
Welge JA, Keck PE Jr, Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression, Psychopharmacology (Berl), 2003;166:1–10.
Robertson C, Idris NR, Boyle P, Beyond classical meta- analysis: can inadequately reported studies be included?, Drug Discov Today, 2004;9:924–31.
Moayyedi P, Meta-analysis: Can we mix apples with oranges?, Am J Gastroenterol, 2004;99:2297–2301.
Gøtzsche PC, Hrobjartsson A, Maric K, Tendal B, Data extraction errors in meta-analyses that use standardized mean differences, JAMA, 2007;298:430–7.
Enck P, Klosterhalfen S, Kruis W, Factors affecting therapeutic placebo response rates in patients with irritable bowel syndrome, Nature Clinical Practice Gastroenterol Hepatol, 2005;2:354–5.
Moreno SG, Sutton AJ, Turner EH, et al., Novel methods to deal with publication biases: secondary analysis of
51. 52. 46. 47. 48. 49. 50. 42.
antidepressant trials in the FDA trial registry database and related journal publications, BMJ, 2009;339:b2981.
37. 38. 39.
Moore RA, McQuay HJ, Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics, Pain, 1997;69;287–4.
Talley NJ, Locke GR, Lahr BD, et al., Predictors of the placebo response in functional dyspepsia, Aliment Pharmacol Ther, 2006;23:923–36.
Vakil N, Laine L, Talley NJ, et al., Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials, Am J Gastroenterol, 2008;103(8):1906–19.
von Arnim U, Peitz U, Vinson B, et al., STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study, Am J Gastroenterol, 2007;102:1268–75.
Vase L, Robinson ME, Verne GN, Price DD, The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation, Pain, 2003;105:17–25.
Verne GN, Robinson ME, Vase L, Price DD, Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients, Pain, 2003;105:223–30.
Vase L, Robinson ME, Verne GN, Price DD, Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms, Pain, 2005;115(3):338–47.
Verne GN, Sen A, Price DD, Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome, J Pain, 2005;6(8):493–6.
Watson A, El-Deredy W, Iannetti GD, et al., Placebo conditioning and placebo analgesia modulate a common brain network during pain anticipation and perception, Pain, 2009;145(1–2):24–30.
Berman SM, Chang L, Suyenobu B, et al., Condition- specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron, Gastroenterology, 2002;123:969–77.
Lieberman MD, Jarcho JM, Berman S, et al., The neural correlates of placebo effects: a disruption account, NeuroImage, 2004;22:447–55.
Kaptchuk TJ, Kelley JM, Conboy LA, et al., Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome, BMJ, 2008;336(7651):999–1003.
Enck P, Klosterhalfen S, The story of O – Is oxytocin the mediator of the placebo response?, Neurogastroenterol Motil, 2009;21:347–50.
Furmark T, Appel L, Henningsson S, et al., A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety, J Neurosci, 2008;28:13066–74.
Lembo AJ, Neri B, Tolley J, et al., Use of serum biomarkers in a diagnostic test for irritable bowel syndrome, Aliment Pharmacol Ther, 2009;29(8):834–42.
Kokkotou E, Conboy LA, Ziogas D, et al., Serum correlates of the placebo effect in Irritable Bowel Syndrome, Neurogastroenterol Motil, 2010;22(3):285–e81.
US GASTROENTEROLOGY & HEPATOLOGY REVIEW
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84
| Page 85
| Page 86
| Page 87
| Page 88
| Page 89
| Page 90
| Page 91
| Page 92
| Page 93
| Page 94
| Page 95
| Page 96
| Page 97
| Page 98
| Page 99
| Page 100